BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 37292195)

  • 1. Efficacy and safety of chimeric antigen receptor T cell therapy in relapsed/refractory diffuse large B-cell lymphoma with different HBV status: a retrospective study from a single center.
    Kong D; Ping N; Gao X; Zou R; Wang P; Wu D; Jin Z; Qu C
    Front Immunol; 2023; 14():1200748. PubMed ID: 37292195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humanized anti-CD19 chimeric antigen receptor-T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection.
    Cui R; Lyu C; Li Q; Jiang Y; Mou N; Yang Z; Liu X; Deng Q; Li L
    Hematol Oncol; 2021 Feb; 39(1):75-86. PubMed ID: 32949412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
    Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients.
    Qu C; Zou R; Wang P; Zhu Q; Kang L; Ping N; Xia F; Liu H; Kong D; Yu L; Wu D; Jin Z
    Front Immunol; 2022; 13():969660. PubMed ID: 36059523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy and safety analysis of the zanubrutinib-based bridging regimen in chimeric antigen receptor T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma].
    Lu Y; Liu H; Ye SG; Zhou LL; Luo X; Dang XY; Yuan XG; Qian WB; Liang AB; Li P
    Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):813-819. PubMed ID: 38049332
    [No Abstract]   [Full Text] [Related]  

  • 6. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma.
    Dong N; Rubio Lopes-Garcia L; Viñal D; Bachmeier C; Shah BD; Nishihori T; Khimani F; Davila ML; Lazaryan A; Pinilla-Ibarz J; Locke FL; Jain MD; Chavez JC
    Transplant Cell Ther; 2023 Jun; 29(6):349.e1-349.e8. PubMed ID: 36878427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus.
    Han L; Zhou J; Zhou K; Zhu X; Zhao L; Fang B; Yin Q; Wei X; Zhou H; Li L; Xu B; Zhang J; Song Y; Gao Q
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32792360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy.
    Ni Y; Gao L; Lu Y; Ye S; Zhou L; Qian W; Liang A; Li P
    Front Immunol; 2022; 13():982346. PubMed ID: 36119029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy].
    Zhou LH; Feng YQ; Hu YX; Huang H
    Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):805-812. PubMed ID: 38049331
    [No Abstract]   [Full Text] [Related]  

  • 10. Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.
    Yuan X; Li X; Huang Y; Jin X; Liu H; Zhao A; Zhang W; Qian W; Liang Y
    Front Immunol; 2022; 13():1015081. PubMed ID: 36505470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HBV reactivation in patients with chronic or resolved HBV infection following BCMA-targeted CAR-T cell therapy.
    Fu S; Zhang Q; Jing R; Zu C; Ni F; Lv Y; Cui J; Zheng H; Zhang Y; Zhang M; Wei G; Cen Z; Chang AH; Hu Y; Huang H
    Bone Marrow Transplant; 2023 Jun; 58(6):701-709. PubMed ID: 37002410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic differences of refractory/relapsed nodal and extranodal diffuse large B-cell lymphoma in the chimeric antigen receptor T cell therapy era.
    Song Z; Xu L; Tang G; Gao L; Wang L; Ni X; Chen L; Chen J; Wang T; Feng D; Yu X; Yang J; Wang Y
    Clin Chim Acta; 2022 Jul; 532():72-78. PubMed ID: 35660013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis.
    Kim J; Cho J; Yoon SE; Kim WS; Kim SJ
    Cancer Res Treat; 2023 Jul; 55(3):1031-1047. PubMed ID: 36915243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric antigen receptor T-cell therapy combined with autologous stem cell transplantation improved progression-free survival of relapsed or refractory diffuse large B-cell lymphoma patients: A single-center, retrospective, cohort study.
    Wang T; Xu L; Gao L; Tang G; Chen L; Chen J; Wang Y; Fu W; Yue W; Ye M; Yu J; Yu X; Feng D; Zhang A; Yang J
    Hematol Oncol; 2022 Oct; 40(4):637-644. PubMed ID: 35141937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant].
    Morita Y; Yagi Y; Kanemasa Y; Sasaki Y; Ishimine K; Hayashi Y; Mino M; Ohigashi A; Tamura T; Nakamura S; Okuya T; Shimizuguchi T; Shingai N; Toya T; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Doki N; Okuyama Y; Ohashi K; Shimoyama T
    Rinsho Ketsueki; 2023; 64(7):586-595. PubMed ID: 37544717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti-CD19-chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B-cell lymphoma and high tumor burden.
    Mu J; Deng H; Lyu C; Yuan J; Li Q; Wang J; Jiang Y; Deng Q; Shen J
    Hematol Oncol; 2023 Apr; 41(2):275-284. PubMed ID: 35195933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of prelymphodepletion absolute lymphocyte counts in relapsed/refractory diffuse large B-cell lymphoma patients treated with chimeric antigen receptor T cells.
    Lu Y; Zhu H; Liu Y; Wang Y; Sun Y; Cheng H; Yan Z; Cao J; Sang W; Zhu F; Li D; Sun H; Zheng J; Xu K; Li Z
    Front Immunol; 2023; 14():1155216. PubMed ID: 37205117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy.
    Hubbeling H; Silverman EA; Michaud L; Tomas AA; Shouval R; Flynn J; Devlin S; Wijetunga NA; Tringale KR; Batlevi C; Dahi P; Giralt S; Lin R; Park J; Scordo M; Sauter C; Shah G; Hajj C; Salles G; Schoder H; Palomba ML; Perales MA; Yahalom J; Imber BS
    Transplant Cell Ther; 2023 Apr; 29(4):259.e1-259.e10. PubMed ID: 36587744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
    Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
    Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysis.
    Avivi I; Perry C; Segman Y; Amit O; Bar-On Y; Katz OB; Gold R; Ribakovsky E; Avigdor A; Vainstein V; Goldschmidt N; Ringelstein-Harlev S; Horowitz NA; Gutwein O; Gurion R; Itchaki G; Abadi U; Nemets A; Sofer O; Vezker M; Tadmor T; Dally N; Filanovsky K; Leiba M; Sarid N; Benyamini N; Luttwak E; Herishanu Y; Ram R
    Ann Hematol; 2022 Apr; 101(4):755-762. PubMed ID: 35083525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.